847728-90-9

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 4-[(1S)-1-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, methyl ester is used as a pharmaceutical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Its ability to modify the properties of other chemicals makes it a valuable component in the development of new medications.
Used in Flavor and Fragrance Industry:
Benzoic acid, 4-[(1S)-1-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, methyl ester is used as a chemical intermediate in the production of various flavors and fragrances. Its unique properties allow it to enhance the stability and shelf life of these products, making it an important component in the creation of long-lasting and high-quality scents and tastes.

Upstream product

• 847728-89-6 (S)-tert-butyl (1-(4-bromophenyl)ethyl)carbamate 
• 201230-82-2 carbon monoxide 
• 67-56-1 methanol 
• 124-38-9 carbon dioxide 
• 917-54-4 methyllithium 
• 24424-99-5 di-tert-butyl dicarbonate 
• 84499-77-4 (S)-α-(p-bromophenyl)ethylamine hydrochloride 

Downstream Products

• 222714-37-6 4-[(1S)-1-aminoethyl]-benzoic acid, methyl ester 
• 1429181-27-0 tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate 
• 1429181-28-1 (S)-tert-butyl 1-(4-((5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)phenyl)ethylcarbamate 
• 1429181-29-2 (S)-1-(4-((5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)phenyl)thanamine 
• 868637-14-3 methyl 4-{(1S)-1-[({5-chloro-2-[methyl(2-phenylethyl)amino]pyridin-3-yl}carbonyl)amino]ethyl}benzoate 
• 868636-95-7 Methyl 4-[(1S)-1-[(5-chloro-2-hydroxybenzoyl)amino]ethyl}benzoate 
• 847729-10-6 methyl 4-[(1S)-1-[(2,5-dichloropyridin-3-yl)formamido]ethyl]benzoate 
• 1429176-51-1 (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one 
• 1429176-78-2 benzyl 4-(4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)benzyl)piperazine-1-carboxylate 
• 1429181-46-3 benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate 
• 1429181-45-2 benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate 
• 1380754-50-6 (S)-methyl 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoate 

Relevant academic research and scientific papers

Discovery and characterization of a potent and selective EP4 receptor antagonist

Abstract EP4 is a prostaglandin E2 receptor that is a target for potential anti-nociceptive therapy. Described herein is a class of amphoteric EP4 antagonists which reverses PGE2-induced suppression of TNFα prod

PHENOXYETHYL PIPERIDINE COMPOUNDS

The present invention provides a compound of the Formula II: Formula II wherein X is: R1 is H, -CN, or F; R2 is H or methyl; R3 is H; and R4 is H, methyl, or ethyl; or R3 and R4 joined toge

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is —O—, —O(C1-C3 alkyl)-; —(C1-C3 alkyl)O—; —C(O)—; —C(═N—O(C1-C3 alkyl))-; —NH— or —NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, —NH(C1-C3alkyl)-; —N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, endometriosis and migraine.

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is -O-, -O(C1-C3 alkyl)-; -(C1-C3 alkyl)O-; -C(O)-; -C(=N-O(C1-C3 alkyl))-; -NH- or -NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is convalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid artrhritis, cancer, endometriosis and migraine.

A novel series of potent and selective EP4 receptor ligands: Facile modulation of agonism and antagonism

A novel series of EP4 ligands, based on a benzyl indoline scaffold, has been discovered. It was found that agonism and antagonism in this series can be easily modulated by minor modifications on the benzyl group. The pharmacokinetic, metabolic

Ortho substituted aryl or heteroaryl amide compounds

This invention provides a compound of the formula (I): wherein X represents a carbon atom or the like: Y represents imino, or the like: Z represents a hydrogen atom or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or th

SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS

This invention provides a compound of the formula (I), wherein X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 in

PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS

This invention provides a compound of the formula (I): wherein A represents a phenyl group or the like: B represents an aryl or the like: E represents a 1,4-phenylene group; R1 and R2 independently represent a hydrogen atom or the li

COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS

The instant invention relates to a combination of an EP4-receptor antagonist and an alpha-2-delta ligand, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly inflammatory,